thrombocytopenia
Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia
April 23, 2024Research and Development Cardiology, Sanofi, clinical trial, thrombocytopenia
Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib 400mg twice daily oral treatment …
Hutchmed announces phase 3 trial met primary endpoint for primary immune thrombocytopenia treatment
August 21, 2023Research and Development HUTCHMED, Haematology, clinical trial, sovleplenib, thrombocytopenia
Hutchmed has announced that its phase 3 trial ESLIM-01 trial assessing the use of sovleplenib has met its primary endpoint …
Revolade gets European go ahead
March 15, 2010Sales and Marketing GlaxoSmithKline, Revolade, thrombocytopenia
European regulators have approved GlaxoSmithKline’s Revolade to treat reduced platelet count in patients with a rare blood disorder. Revolade (eltrombopag) …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
